THE WOODLANDS, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it will present data from two studies related to LX9851, its investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback